Literature DB >> 33686265

Advancing oncolytic virus therapy by understanding the biology.

Howard L Kaufman1, Dawid Maciorowski2.   

Abstract

Year:  2021        PMID: 33686265     DOI: 10.1038/s41571-021-00490-4

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective.

Authors:  Egle Ramelyte; Aizhan Tastanova; Zsolt Balázs; Desislava Ignatova; Patrick Turko; Ulrike Menzel; Emmanuella Guenova; Christian Beisel; Michael Krauthammer; Mitchell Paul Levesque; Reinhard Dummer
Journal:  Cancer Cell       Date:  2021-01-21       Impact factor: 31.743

  1 in total
  4 in total

1.  Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1.

Authors:  Dafne C A Quixabeira; Victor Cervera-Carrascon; Joao M Santos; James H A Clubb; Tatiana V Kudling; Saru Basnet; Camilla Heiniö; Susanna Grönberg-Vähä-Koskela; Marjukka Anttila; Riikka Havunen; Anna Kanerva; Akseli Hemminki
Journal:  Oncoimmunology       Date:  2022-01-22       Impact factor: 8.110

Review 2.  Immunological configuration of ovarian carcinoma: features and impact on disease outcome.

Authors:  Jitka Fucikova; An Coosemans; Sandra Orsulic; David Cibula; Ignace Vergote; Lorenzo Galluzzi; Radek Spisek
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 13.751

3.  Cancer gene therapy goes viral: viral vector platforms come of age.

Authors:  Urban Bezeljak
Journal:  Radiol Oncol       Date:  2022-02-11       Impact factor: 2.991

Review 4.  Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response.

Authors:  Dong-Rui Wang; Xian-Lin Wu; Ying-Li Sun
Journal:  Signal Transduct Target Ther       Date:  2022-09-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.